ReviewAmerican journal of clinical dermatology2020
Emerging Therapeutic Options for Chronic Pruritus.
Review in American journal of clinical dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 36 citations in OpenAlex.
- Analysis of treatment pathways and long-term prevalence of pruritus after burn - An observational study with real-world data.Burns : journal of the International Society for Burn Injuries · 2026Observational
- Psychopharmacology in Dermatology.Indian dermatology online journal · 2026Article
- Pruritus in Palliative Care: A Narrative Review of Essential Oil-Based Strategies to Alleviate Cutaneous Discomfort.Diseases (Basel, Switzerland) · 2025Review
- Therapeutic challenges and novel treatment options in psychogenic pruritus.Archives of dermatological research · 2024Article
- Prurigo nodularis: new insights into pathogenesis and novel therapeutics.The British journal of dermatology · 2024Review
- Emerging trends and hotspots of the itch research: A bibliometric and visualized analysis.CNS neuroscience & therapeutics · 2024Article
- Endogenous Opioid Imbalance as a Potential Factor Involved in the Pathogenesis of Chronic Kidney Disease-Associated Pruritus in Dialysis Patients.Journal of clinical medicine · 2023Article
- Serum Level of Protein-Bound Uraemic Toxins in Haemodialysis Patients with Chronic Kidney Disease-Associated Pruritus: Myths and Facts.Journal of clinical medicine · 2023Article
- Elevated Level of Serum Neurotrophin-4, but Not of Brain-Derived Neurotrophic Factor, in Patients with Chronic Kidney Disease-Associated Pruritus.Journal of clinical medicine · 2022Article
- Evaluating the Effectiveness of Intranasal Butorphanol in Reducing Chronic Itch.Acta dermato-venereologica · 2022Article
- An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects.Pharmacological research · 2022Review
- Interleukin-31 as a Clinical Target for Pruritus Treatment.Frontiers in medicine · 2021Review
- Involvement of Neuro-Immune Interactions in Pruritus With Special Focus on Receptor Expressions.Frontiers in medicine · 2021Review
- Biologicals in Treatment of Chronic Urticaria: A Narrative Review.Indian dermatology online journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pruritus, defined as an unpleasant sensation resulting in a need to scratch that lasts more than 6 weeks, is a prevalent and bothersome symptom associated with both cutaneous and systemic conditions. Due to complex pathogenesis and profuse contributing factors, chronic pruritus therapy remains challenging. Regardless of the well-established antipruritic properties of classic pharmacotherapy (topical therapy, phototherapy and systemic therapy), these methods often provide insufficient relief for affected individuals. Owing to the growing interest in the field of pruritic research, further experimental and clinical data have emerged, continuously supporting the possibility of instigating novel therapeutic measures. This review covers the most relevant current modalities remaining under investigation that possess promising perspectives of approval in the near future, especially opioidergic drugs (mu-opioid antagonists and kappa-opioid agonists), neurokinin-1 receptor antagonists, biologic drugs, Janus kinase inhibitors, ileal bile acid transporter inhibitors, aryl hydrocarbon receptor agonists and histamine H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.